John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly sold 8,149 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total value of $31,292.16. Following the completion of the sale, the chief financial officer directly owned 125,883 shares of the company’s stock, valued at $483,390.72. The trade was a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

John Alexander Kelly also recently made the following trade(s):

• On Wednesday, January 21st, John Alexander Kelly sold 15,213 shares of Precision BioSciences stock. The shares were sold at an average price of $4.03, for a total value of $61,308.39.

Precision BioSciences Stock Performance

Shares of NASDAQ:DTIL traded up $0.07 during trading on Thursday, reaching $3.92. The company had a trading volume of 214,558 shares, compared to its average volume of 225,532. The firm has a market capitalization of $89.77 million, a price-to-earnings ratio of -0.47 and a beta of 1.31. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45. The stock’s fifty day moving average price is $4.16 and its 200 day moving average price is $5.01. Precision BioSciences, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $8.82.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Empery Asset Management LP purchased a new position in shares of Precision BioSciences in the 4th quarter worth $9,130,000. Aberdeen Group plc acquired a new stake in Precision BioSciences during the fourth quarter worth about $8,897,000. Boothbay Fund Management LLC raised its holdings in shares of Precision BioSciences by 497.1% in the 4th quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock worth $4,435,000 after purchasing an additional 887,515 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Precision BioSciences in the 4th quarter worth about $3,320,000. Finally, Bleichroeder LP lifted its stake in shares of Precision BioSciences by 54.7% in the 4th quarter. Bleichroeder LP now owns 1,662,500 shares of the company’s stock valued at $6,916,000 after purchasing an additional 587,500 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $60.00.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.